Engrail Therapeutics Adds $32M In Series A Funding

San Diego-based pharmaceuticals startup Engrail Therapeutics, which is focused on neuroscience pharmaceuticals, said today that it has raised an additional $32M in its Series A funding round, bringing its total raised in the Series A to $64M. The new funding was led by Nan Fung Life Sciences (NFLS). According to the company, the new funding will go towards advancing its pipeline, including lead assets ENX-101, ENX-102 and internal preclinical programs. The company is focused on treating diseases of the nervous system.